Literature DB >> 14693108

Dementia with Lewy bodies.

Ian McKeith1, Jacobo Mintzer, Dag Aarsland, David Burn, Helen Chiu, Jiska Cohen-Mansfield, Dennis Dickson, Bruno Dubois, John E Duda, Howard Feldman, Serge Gauthier, Glenda Halliday, Brian Lawlor, Carol Lippa, Oscar L Lopez, João Carlos Machado, John O'Brien, Jeremy Playfer, Wayne Reid.   

Abstract

Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein alpha-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

Entities:  

Mesh:

Year:  2004        PMID: 14693108     DOI: 10.1016/s1474-4422(03)00619-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  177 in total

1.  Glucocerebrosidase mutations in diffuse Lewy body disease.

Authors:  Kenya Nishioka; Owen A Ross; Carles Vilariño-Güell; Stephanie A Cobb; Jennifer M Kachergus; David M A Mann; Julie Snowden; Anna M T Richardson; David Neary; Christopher A Robinson; Alex Rajput; Spiridon Papapetropoulos; Deborah C Mash; Rajesh Pahwa; Kelly E Lyons; Zbigniew K Wszolek; Dennis W Dickson; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2011-01       Impact factor: 4.891

Review 2.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND.

Authors:  Prashanthi Vemuri; Gyorgy Simon; Kejal Kantarci; Jennifer L Whitwell; Matthew L Senjem; Scott A Przybelski; Jeffrey L Gunter; Keith A Josephs; David S Knopman; Bradley F Boeve; Tanis J Ferman; Dennis W Dickson; Joseph E Parisi; Ronald C Petersen; Clifford R Jack
Journal:  Neuroimage       Date:  2010-12-31       Impact factor: 6.556

4.  Risk of decline in functional activities in dementia with Lewy bodies and Alzheimer disease.

Authors:  Dawn P Gill; Thomas D Koepsell; Rebecca A Hubbard; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jan-Mar       Impact factor: 2.703

5.  Amnestic mild cognitive impairment with low myocardial metaiodobenzylguanidine uptake.

Authors:  Ryuji Sakakibara; Takeshi Ogata; Masayuki Haruta; Masahiko Kishi; Yohei Tsuyusaki; Akihiko Tateno; Fuyuki Tateno; Takayuki Mouri
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

Review 6.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  Gene expression profiling of brain samples from patients with Lewy body dementia.

Authors:  Maciej Pietrzak; Audrey Papp; Amanda Curtis; Samuel K Handelman; Maria Kataki; Douglas W Scharre; Grzegorz Rempala; Wolfgang Sadee
Journal:  Biochem Biophys Res Commun       Date:  2016-09-22       Impact factor: 3.575

8.  Incidence of dementia with Lewy bodies and Parkinson disease dementia.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; Bradley F Boeve; J Eric Ahlskog; Walter A Rocca
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

9.  LRRK2 variation and dementia with Lewy bodies.

Authors:  Michael G Heckman; Alexandra I Soto-Ortolaza; Monica Y Sanchez Contreras; Melissa E Murray; Otto Pedraza; Nancy N Diehl; Ronald Walton; Catherine Labbé; Oswaldo Lorenzo-Betancor; Ryan J Uitti; Jay van Gerpen; Nilüfer Ertekin-Taner; Glenn E Smith; Kejal Kantarci; Rodolfo Savica; David T Jones; Jonathan Graff-Radford; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Rosa Rademakers; Zbigniew K Wszolek; Neill R Graff-Radford; Tanis J Ferman; Dennis W Dickson; Bradley F Boeve; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2016-07-29       Impact factor: 4.891

10.  Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study.

Authors:  Alexander V Lebedev; E Westman; M K Beyer; M G Kramberger; C Aguilar; Z Pirtosek; D Aarsland
Journal:  J Neurol       Date:  2012-12-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.